Clinical Trial Search

Primary: Number of Patients With a Modified Rankin Scale (mRS) Score of 0-1 at 3 Months — 38 participants

Primary: Percentage of Participants With Ovulation — 79.1; 82.6 percentage of participants

Primary: Comparison of Virologic Response at Week 24 Using Lower Limit of Quantification (LLOQ) = 50 Copies/mL, Full Analysis Set Population — 137; 276; 11; 19 participants

Primary: Clinician Overall Satisfaction With Catheter Securement — 2.27; 1.63 Units on a scale

Primary: Change From Baseline in the Positive and Negative Syndrome Scale-Excited Component (PANSS-EC) Total Score up to 2 Hours After the First Intramuscular (IM) Injection…

Primary: HbA1c Change From Baseline at Week 52 — -0.36; -0.57 Percent — p=0.0005

Primary: Change From Baseline in Average Daily Frequency of Moderate or Severe Hot Flashes After 4 Weeks of Treatment — -7.0; -6.9; -5.4 Hot flashes — p=0.0024

Primary: TIV Comparisons: Percentage of Participants Achieving at Least a 4-fold Increase in the Titer of the Standard Hemagglutination Inhibition Assay (HAI) — 80.3; 78.6; 58.0…

Primary: Peak Inspiratory Capacity (IC) After 21 Days of Treatment — 2.69; 2.48; 2.63 Liters

Primary: Number Participants With Days Per Week With Global Flushing Severity Score (GFSS) ≥4 Partitioned Into 6 Categories During the Postwithdrawal Period — 291; 181; 188; 43…

Primary: Geometric Mean of Haemagglutination Inhibiting (HI) Antibodies Titers Against the Three Strains. — 46.0; 45.8; 320.9; 329.4 Titers

Primary: Target Lesion Failure (TLF) — 3.2 percentage of participants — p=<0.0001

Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 102; 3 Participants

Primary: Percentage of Participants Who Experienced the Occurence of Peptic Ulcer(s). — 1.35; 1; 6.58 percentage of participants

Primary: 5-Day Sum of Pain Intensity Difference (SPID5) — 98.6; 153.1; 161.8; 218.4 Units on a scale — p=0.007